LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
E Crusoea, T Faconb, P Moreauc, I Spickad, K Suzukie, K Yongf, J Mikhaelg, T Fukaoh, N Armstrongi, T Martinj
a Hospital Universitario Professor Edgar Santos (HUPES), Salvador, Brazil; Rede D'or Oncologia, Salvador, Brazil
b Lille University Hospital, Lille, France
c University Hospital Hôtel-Dieu, Nantes, France
d 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
e Japanese Red Cross Medical Center, Tokyo, Japan
f University College Hospital, London, United Kingdom
g Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, United States
h Sanofi, Global Oncology, Cambridge, United States
i Sanofi, Global Medical Affairs, Cambridge, United States
j University of California San Francisco Medical Center, San Francisco, United States
Ver másLido
227
Vezesque se leu este artigo
114
Total PDF
113
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Maio | 26 | 21 | 47 |
| 2024 Abril | 33 | 12 | 45 |
| 2024 Março | 18 | 16 | 34 |
| 2024 Fevereiro | 9 | 11 | 20 |
| 2024 Janeiro | 7 | 9 | 16 |
| 2023 Dezembro | 6 | 15 | 21 |
| 2023 Novembro | 10 | 19 | 29 |
| 2023 Outubro | 4 | 11 | 15 |
